Treace Medical Concepts (TMCI) Expected to Announce Quarterly Earnings on Thursday

Treace Medical Concepts (NASDAQ:TMCIGet Free Report) is projected to announce its earnings results after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $67.19 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Treace Medical Concepts Price Performance

TMCI opened at $9.61 on Wednesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.98 and a current ratio of 4.12. Treace Medical Concepts has a 52-week low of $3.92 and a 52-week high of $14.81. The stock has a market capitalization of $598.70 million, a PE ratio of -9.71 and a beta of 0.75. The stock’s 50 day moving average price is $8.77 and its 200-day moving average price is $7.18.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Truist Financial boosted their target price on Treace Medical Concepts from $7.00 to $8.40 and gave the stock a “hold” rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $8.00 price target on shares of Treace Medical Concepts in a report on Tuesday, December 17th. Lake Street Capital initiated coverage on Treace Medical Concepts in a report on Tuesday, December 31st. They set a “buy” rating and a $14.50 price target on the stock. Stifel Nicolaus upped their price objective on Treace Medical Concepts from $7.00 to $8.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. Finally, BTIG Research upgraded Treace Medical Concepts from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a research report on Tuesday, February 4th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $9.99.

Read Our Latest Stock Report on TMCI

Treace Medical Concepts Company Profile

(Get Free Report)

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.

Featured Stories

Earnings History for Treace Medical Concepts (NASDAQ:TMCI)

Receive News & Ratings for Treace Medical Concepts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Treace Medical Concepts and related companies with MarketBeat.com's FREE daily email newsletter.